About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

RECRUITINGPhase 1NCT07291232

A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity

This study is to assess adverse events, change in body weight and pharmacokinetics in adult participants with obesity receiving ABBV-295 subcutaneous injections or matching placebo.

Lead sponsor: AbbVie•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Contacts

ABBVIE CALL CENTER

CONTACT

844-663-3742 abbvieclinicaltrials@abbvie.com

Sponsors

Lead Sponsor

AbbVie

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•BMI ≥ 30.0 to ≤ 45.0 kg/m2 after rounding to the tenths decimal at Screening (BMI is calculated as weight in kg divided by the square of height measured in meters) with or without weight related stable comorbidities (e.g., hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease).
•A female who is not pregnant or breastfeeding and is not considering becoming pregnant or donating eggs during the study or for approximately 60 days after the last dose of study treatment.

Exclusion Criteria

•Participant has a self-reported change in body weight ≥ 5% within 3 months prior to Screening.
•HbA1c ≥ 6.5% and/or serum glucose ≥ 126 mg/dL at Screening.
•Participant has taken a medication for the purpose of treating obesity or has been enrolled in an obesity trial within 180 days prior to study treatment administration.

Related studies

RECRUITINGPhase 3

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes

NCT07351045 · Obesity or Overweight

RECRUITINGPhase 3

Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

NCT07037459 · Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction, and more

The ISAR InflEx Trial (Inflammation and Exercise)

NCT07543666 · Inflammation, Obesity (Disorder)

RECRUITINGPhase 1

A Study to Learn About the Effect of Study Medicine Called PF-08653944 on How Quickly the Stomach Empties Its Content in Healthy Adults With Overweight or Obesity

NCT07508241 · Obesity, Overweight and/or Obesity, and more

Dietary Peanuts and Nutrition-Related Outcomes

NCT07244458 · Dietary Change, Obesity & Overweight, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: December 18, 2025Terms

Trial snapshot

StatusRECRUITING

PhasePHASE1

Enrollment96

Start dateNov 2025

Last updatedDec 18, 2025

Condition

Locations shown

Acpru /Id# 278624

Grayslake, Illinois

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 18, 2025Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions